Cancer-targeted immunotherapies, both cellular and antibody-mediated, are poised to deliver transformative improvements in cancer treatment, with significant advances already evident in haematological and solid tumours. Fundamental research in the CIIC  is focused on three key themes, each critical to development of such novel treatments.

One focus is on identifying and characterising recognition of tumour antigens, and a second on understanding and therapeutically manipulating the tumour microenvironment. In a third theme, CIIC members are carrying out pre-clinical studies on a wide range of immunotherapeutic strategies, including new T cell  targeting,  vaccination, antibody-based, and chemotherapy-based approaches,  with the ultimate aim of advancing these novel therapeutic concepts into clinical trials.

To view associated news stories click here.

To view our list of upcoming scientific conferences click here.

  • Tumour Antigen Choice

    With the advent of powerful therapeutic options such as antibody therapy, TCR gene transfer, and chimeric antigen receptors, tumour antigen selection is emerging as a critical…

    More >
  • Tumour Microenvironment

    The tumour microenvironment can be strongly immunosuppressive, and represents a potential axis for therapeutic intervention. CIIC members are focussed on understanding  and therapeutically targeting the microenvironment …

    More >
  • Immunotherapeutic Strategies

    CIIC members are focused on developing immunotherapeutic strategies based on key approaches such as vaccination, antibody immunotherapy, adoptive transfer, and TCR gene transfer, several of which…

    More >